Major surgery, radiotherapy, or systemic therapy within 3 weeks of the start of treatment was not allowed, with the exception of palliative radiotherapy to nontarget metastatic lesions.
All reasons for HC services were included and all patients aged 18 or older at the time of service were included, with the exception of palliative clients, because of differences in their expected clinical course.
Patients had experienced progression of disease (PD) or intolerance to at least 1 prior systemic therapy (except for ocular primary tumor patients, who were required to have local control of their disease), with the last therapy administered ≥28 days before trial entry (with the exception of palliative radiotherapy).
Treatment with chemo-, hormone-, immuno- or radiotherapy was not permitted, with the exception of bisphosphonates and palliative radiotherapy to non-target lesions.
All stroke survivors >18 years of age with confirmed stroke within the previous 14 days were eligible, with the exception of those receiving palliative care or those with severe pre-morbid disability (modified Rankin Score = 5) [ 28].
Patients in all phases of their treatment were included, receiving surgical treatment, chemotherapy, radiotherapy, immune therapy or hormonal treatment, with the exception of patients in a palliative phase, who were excluded through their DRG code.
With the exception of resectable liver/lung metastases, palliative resection in mCRC patients has been performed previously only to relieve symptoms or in emergent medical situations (perforation, obstruction, or bleeding) and clinicians generally choose systemic chemotherapy in asymptomatic mCRC patients.
This must be borne in mind when interpreting these findings, especially in view of the fact that previous studies have, with few exceptions, concerned a later stage of palliative or terminal care.
There is little research examining potential spatial access to any form of palliative care service, though there are some exceptions [ 17– 17].
There were no differences in age, stage at diagnosis, total number of cycles of palliative chemotherapy, incidence of visceral metastasis, and metastatic sites with the exception of liver among breast cancer subtypes.
Current treatment options for MPNs, and especially for primary myelofibrosis, are limited and largely palliative with the notable exception of allogeneic stem cell transplantation.
